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Role of platelets in occlusion after coronary revasculariza-
tion. Occlusion after coronary revascularization by coro-
nary bypass surgery, percutaneous transluminal coronary
angioplasty or thrombolysis is an important factor leading to
recurrent ischemia and associated morbidity and mortality.
Vascular injury, as well as residual lumen stenosis, has been
implicated in the pathogenesis of occlusion after each of
these procedures. A central focus in this occlusion process
has been the platelet. Vascular injury results in adhesion of
platelets to the damaged endothelium or exposed subendo-
thelium; here, exposure to collagen causes platelet activa-
tion and release of adenosine, thromboxane Az and seroto-
nin, all of which amplify platelet aggregation and promote
thrombus formation. In addition, alpha-thrombin further
activates platelet aggregation, and the high shear rate asso-
ciated with important residual stenosis favors platelet acti-
vation. In each of the three revascularization procedures,
risk of acute occlusion is highest early after the procedure,
when platelet activation resulting from the procedure (vas-
cular injury, cardiopulmonary bypass, heparin administra-
tion, for example) would be anticipated to be greatest.
Further supporting the role of platelets in the process of
occlusion are clinical trial data indicating that antiplatelet
agents given before or early after each of these procedures
reduce the frequency of early events related to occlusion.
Antiplatelet therapy and vein graft occlusion. After saphe-
nous vein bypass grafting, approximately 8% to 18% of distal
anastomoses are occluded by 1 month (1), and approxi-
mately 50% of vein grafts will be occluded or show severe
atherosclerosis by about 10 years (2). This late occlusive
process is thought to be related to a hyperplastic prolifera-
tive response, probably also influenced by platelet-derived
growth factors (3). These results do not apply to internal
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mammary artery grafts, which have significantly better pa-
tency rates. Antiplatelet therapy with aspirin, with or with-
out dipyridamole, is associated with a decrease in the
frequency of early saphenous vein bypass graft occlusion
(4-6), Current practice is to initiate therapy in either the
preoperative or the immediate postoperative period, because
benefit appears to be lost if antiplatelet therapy is not
initiated within the first several days postoperatively. Aspi-
rin administered before surgery obviously carries the risk of
increased frequency of bleeding.
Current study: identifying patients at highest risk for vein
graft occlusion. In the current issue of the Journal, Gav-
aghan et a1. (7) suggest that patients at highest risk for
saphenous bypass graft occlusion may be identified preoper-
atively by evidence of platelet activation. This finding was
not predicted by clinical class but may relate to recurrent
asymptomatic ischemia or naturally occurring vascular in-
jury in the form of plaque fissuring, or both. Elevation of
beta-thromboglobulin levels in the control group strongly
supports their view that platelet activation is present in a
subgroup most likely to develop saphenous bypass occlu-
sion. It is also probable that these are the patients most likely
to benefit from antiplatelet therapy. If these findings can be
confirmed by use of other indexes of platelet activation in
prospective trials, it may be possible to identify preopera-
tively the subgroup at high risk for graft occlusion. Other
factors could also be incorporated into a multivariate model
to predict those at greatest risk, Accordingly, in these
patients antiplatelet therapy could be initiated preopera-
tively and titrated until evidence for platelet activation is
maximally suppressed,
The hypothesis of Gavaghan et a1. (7) is particularly
attractive in view of recent advances in our understanding of
the molecular mechanisms involved in platelet biology.
Platelets represent a specific fragment whose main biologic
functions are adhering to areas of vessel wall injury and
aggregating to form a hemostatic plug. These functions also
initiate injury repair through the actions of a number of
vascular growth factors. AggregatioIl appears to be depen-
dent on specific receptors, a relation that has led to the
development of receptor-specific antiplatelet therapy. Early
studies (8) in primate models suggest that dose-dependent
blockade of platelet thrombus formation is possible with use
of monoclonal antibodies to the platelet GPIIb/IIIa receptor.
This approach appears to offer the promise of preventing
vaso-occlusive thrombus formation while preserving enough
functional GPIIb/IIIa receptors to maintain a nearly normal
bleeding time. In the future, it may be possible to employ
these specific inhibitors of platelet receptors preoperatively
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Developing specific antiplatelet therapies for specific revas-
cularization procedures. Likewise, it may be possible to
develop similar risk factor characterization followed by
specific therapy to achieve selective antithrombotic therapy
after other forms of coronary revascularization, such as
coronary angioplasty and thrombolytic therapy. Although
platelet aggregation has also been implicated in occlusion
after these procedures, the amount of residual thrombus and
vascular injury and the relative amount of platelet aggrega-
tion are likely to be quite different after each of these
procedures. In addition, the status of these variables after
angioplasty and after thrombolysis is also likely to differ
from that after saphenous vein bypass grafting. Therefore, it
is not unreasonable to expect that different forms of anti-
platelet therapy may be required for each of these proce-
dures.
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